Neuralstem, Inc. (CUR) Files FDA Application for First Chronic Spinal Cord Injury Stem Cell Trial
Neuralstem Inc. has patented technology which enables the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities. The company today announced that it has filed an Investigational New Drug (IND) application with the US Food and Drug Administration (FDA) to begin a Phase I safety clinical trial for chronic spinal cord injury with its spinal cord stem cells. This Phase I safety trial will enroll a total of 16 long-term spinal cord injury patients that have complete paralysis. The proposed trial is primarily designed to test the safety of both Neuralstem's cells and…